AI Article Synopsis
- Smoking is a significant problem among individuals with schizophrenia, with about 90% of them reported to smoke.
- This article reviews various smoking cessation interventions and their neuropsychiatric effects on these patients.
- The review included 18 studies, showing that nicotine replacement therapy, bupropion, and varenicline are effective in helping patients either quit or significantly reduce their smoking.
Article Abstract
Smoking cessation is a chronic issue surrounding individuals with schizophrenia. It is estimated that up to 90% of patients diagnosed with schizophrenia smoke cigarettes. The purpose of this article is to provide a nonsystematic review of the efficacy of smoking cessation interventions as well as to explore the potential neuropsychiatric adverse effects of these agents in patients with schizophrenia. Eighteen studies were found and included in the review. Overall, nicotine replacement therapy, bupropion, and varenicline have all proven their effectiveness at either promoting smoking abstinence or a significant reduction in cigarette use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007740 | PMC |
| http://dx.doi.org/10.9740/mhc.2018.03.078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!